Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612273 | 0.83 | MAPT (0.33) | MAPT | |
| SCHEMBL18782487 | 0.77 | SLC6A2 (0.37) | — | |
| SCHEMBL24106028 | 0.73 | TSHR (0.31) | — | |
| SCHEMBL20977931 | 0.72 | SELE (0.34) | MAPK1L3MBTL1 | |
| SCHEMBL20718668 | 0.71 | CHRNB2 (0.33) | MAPK1L3MBTL1 | |
| SCHEMBL19986722 | 0.71 | ITGB1 (0.45) | MAPTMAPK1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL27187938 | 0.69 | MAPT (0.35) | MAPT | |
| SCHEMBL25468864 | 0.69 | CXCR2 (0.38) | MAPTMAPK1L3MBTL1 | |
| SCHEMBL27187940 | 0.69 | MAPT (0.35) | MAPT | |
| SCHEMBL21937398 | 0.69 | MAPT (0.34) | MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | MAPT 4397/4885MAPK1 128/4885L3MBTL1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.